Sarepta won’t reopen enrollment in Duchenne gene therapy trial

ENVISION will analyze existing data from 90 patients after prolonged safety hold

Written by Michela Luciano, PhD |

A bell labeled UPDATE is flanked by two smaller, ringing bells.

Sarepta Therapeutics will not reopen enrollment in a global clinical trial testing its gene therapy Elevidys (delandistrogene moxeparvovec-rokl) in boys and men with Duchenne muscular dystrophy (DMD), the company announced in a community letter.

The Phase 3 trial, called ENVISION (NCT05881408), was designed to assess Elevidys’ safety and effectiveness in late-ambulatory patients (those who can still walk but have increasingly limited walking ability) and non-ambulatory patients (those who cannot walk).

Recommended Reading
Two people, one in a wheelchair and one walking, are seen together on a tree-lined path.

New AI-based tool may predict when Duchenne kids will lose ability to walk

ENVISION placed on hold following two deaths from liver failure

The study was placed on hold last year following the deaths of two non-ambulatory patients who developed acute liver failure after receiving Elevidys.

After more than a year on hold, Sarepta has decided not to reopen enrollment and instead will analyze the blinded data collected during the study’s first part. The trial enrolled 90 participants across 14 countries, including 64 non-ambulatory and 26 late-ambulatory individuals.

In response, Parent Project Muscular Dystrophy (PPMD) acknowledged that the decision may leave families disappointed and uncertain about what comes next.

“The decision to close ENVISION is disappointing news for the individuals and families who have been following and participating in the trial,” PPMD said in an update. “We recognize the hope, time, and commitment that families have invested in this research, and understand that this update may bring difficult questions and uncertainty.”

PPMD added: “Our commitment is to provide clear, accurate, and trusted information to help make sense of what these updates mean for our community, what we know, what questions remain, and what may come next.”

Sarepta said trial sites are working directly with participants and their families to discuss individual next steps and transition plans.

“We recognize how much individuals and families contribute when they participate in clinical research,” said Wendy Erler, senior vice president of patient affairs at Sarepta, in the community letter. “We are committed to respecting the contributions of every participant and supporting families through the next steps.”

Elevidys approval now limited to patients who can still walk

DMD is caused by mutations in the DMD gene that prevent the production of functional dystrophin, a protein that protects muscles from damage during movement. Without dystrophin, muscles progressively weaken, affecting walking, breathing, and everyday activities.

Elevidys, formerly known as SRP-9001, uses a modified virus to deliver genetic instructions into muscle cells to produce a shorter but functional version of dystrophin. The one-time gene therapy is given as a single infusion into a vein (intravenous) and is designed to improve motor function.

Elevidys initially received accelerated approval in the U.S. in 2023 for children with DMD ages 4 to 5 who could walk. In 2024, the U.S. Food and Drug Administration (FDA) expanded its approval to patients ages 4 and older, granting full approval for those who could still walk and accelerated approval for those who could no longer walk.

Accelerated approval allows the FDA to approve a treatment based on early evidence that it is likely to provide clinical benefits. Additional testing is then required to confirm those benefits.

ENVISION was launched in 2023. In the U.S., it was proposed as a confirmatory study to verify the therapy’s clinical benefit in non-ambulatory patients.

We recognize the hope, time, and commitment that families have invested in this research, and understand that this update may bring difficult questions and uncertainty.

  

The study was designed to have two parts. In the first, participants were randomly assigned to Elevidys or a placebo. After 72 weeks, or about 1.4 years, participants given the placebo would receive Elevidys, while those who received Elevidys would receive the placebo.

Following the two reported deaths, the FDA restricted Elevidys’ approval in November 2025 to ambulatory patients ages 4 and older. Sarepta also began investigating additional safety measures aimed at reducing the risk of serious liver complications in non-ambulatory patients.

The proposed enhanced safety regimen combines an oral immunosuppressive medicine called sirolimus with corticosteroids. Researchers are evaluating this approach in the eighth group of participants, known as Cohort 8, in the ongoing Phase 1 ENDEAVOR trial (NCT04626674). The trial is recruiting non-ambulatory DMD patients at several sites across the U.S.

According to Sarepta, if ENDEAVOR results support the new safety regimen, restarting ENVISION would require non-ambulatory participants to receive blinded sirolimus alongside corticosteroids before treatment. That would mean combining data from participants treated under different safety regimens, making it harder to interpret the results under ENVISION’s original design.

Sarepta therefore decided to close enrollment and analyze the blinded data already collected during ENVISION’s first part. The company said this approach would allow it to share meaningful, reliable findings with the DMD community sooner.

What comes next for ENVISION trial participants

Once the study database is closed, participants will learn from their study doctors whether they received Elevidys or the placebo. Their next steps will depend on which treatment they received.

Those who received Elevidys will be invited to join the EXPEDITION study (NCT05967351), which is evaluating the gene therapy’s long-term safety and effects. Participants who received the placebo may have an opportunity to receive Elevidys through an open-label crossover, meaning both patients and their doctors would know they are receiving the gene therapy.

The potential crossover will depend on results from ENVISION’s first part and safety findings from ENDEAVOR Cohort 8, as well as Data Monitoring Committee and regulatory review and authorization to lift the clinical hold.

Sarepta expects to meet with the FDA in early 2027 to discuss the available safety data and a potential path forward for Elevidys in non-ambulatory DMD patients.

“We remain committed to researching a potential development path for non-ambulatory individuals living with Duchenne,” Erler said.

Sarepta also highlighted new Elevidys findings presented at recent scientific meetings. These included two-year results suggesting sustained motor benefits in ambulatory patients treated at ages 8–12, compared with a well-matched untreated group. Other early findings showed that children treated at ages 2–3 had Elevidys-produced dystrophin in their muscle tissue 12 weeks after treatment. Sarepta noted that continued follow-up is needed to determine how these early findings translate into longer-term clinical outcomes.

The company also confirmed that the FDA is expected to decide by the end of February 2027 whether to grant traditional approval for Amondys 45 (casimersen) and Vyondys 53 (golodirsen), two exon-skipping therapies designed to treat certain people with DMD.

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.